Published • loading... • Updated
Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder
The application seeks to advance a dual-targeting siRNA therapy that could offer a new approach for patients with mixed and severe dyslipidemia.
Summary by Morgan County Citizen
2 Articles
2 Articles
Morgan County CitizenReposted by 
The Manila Times
The Manila TimesRibo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder
SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for…
·Madison, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
